We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GeoVax

News List

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development B3C newswire
November 06, 2023
ProBioGen and GeoVax Labs, announce the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly firstwordpharma
August 20, 2021
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today presented data from ongoing studies of its preventive vaccine against COVID-19.
GeoVax Expands Intellectual Property Portfolio americanpharmaceuticalreview
March 09, 2021
GeoVax Labs announced the filing of two additional patent applications important to the Company’s key focus on vaccines against SARS-CoV-2 (COVID-19) and cancer immunotherapies.